Crucell « Terug naar discussie overzicht

Acambis -Bavarian Nordic

15 Posts

Omlaag ↓

[verwijderd] 26 augustus 2005 07:40

Acambis turns to America in defence of patent claim

By Stephen Foley
Published: 25 August 2005

Acambis, the Cambridge-based vaccines company which developed a jab against smallpox, is set to rely on its relationship with the US government as it prepares to defend allegations of stealing trade secrets and breaching a rival's patents.

The company was served with a claim for damages last week by its Danish rival, Bavarian Nordic, which claims Acambis used secrets revealed to it in licensing negotiations in 2002.

The two are in an increasingly bitter race to develop a second-generation smallpox vaccine that the US government can use to inoculate people whose immune systems are too weak to take traditional vaccines. The victor could win a contract worth $1bn (£555m). And Acambis's lawyers are drawing up a robust defence that claims the US government itself gave the company the detailed scientific knowledge it has used. That science is not patent-protected, Acambis will argue.

Details of Bavarian Nordic's specific allegations have emerged in court papers from the US. These say Acambis's chief scientific officer, Thomas Monath, and a team from the company were shown details of clinical data, dosing and production conditions for the weakened smallpox vaccine - MVA - at a meeting at Acambis's offices on 12 June 2002. The companies signed a "secrecy agreement" before the meeting, it is alleged. Acambis requested a licensing proposal, but backtracked, it is claimed.

The two sides were negotiating a deal whereby Acambis would license intellectual property surrounding MVA. But Acambis signed a deal with the US government's National Institutes of Health (NIH), which had been working on MVA. Bavarian says the NIH was using its secrets, which were not the US government's to sign away.

It tried unsuccessfully to prevent the NIH from releasing its MVA strain to Acambis, the court documents reveal. "The virus was originally provided to Dr Moss [Bernard Moss of the NIH] for research and not for commercialisation into vaccine products," it claims.

The NIH was keen to generate a competitive tender for the contract to supply up to 80 million doses of MVA, which could be worth $1bn. It faced domestic criticism for awarding a contract for a stockpile of anthrax drugs to a single supplier, and it is expected that the MVA contract will be shared between Acambis and Bavarian Nordic.

Acambis refused to comment yesterday on the specifics revealed in the court documents.

Acambis, the Cambridge-based vaccines company which developed a jab against smallpox, is set to rely on its relationship with the US government as it prepares to defend allegations of stealing trade secrets and breaching a rival's patents.

The company was served with a claim for damages last week by its Danish rival, Bavarian Nordic, which claims Acambis used secrets revealed to it in licensing negotiations in 2002.

The two are in an increasingly bitter race to develop a second-generation smallpox vaccine that the US government can use to inoculate people whose immune systems are too weak to take traditional vaccines. The victor could win a contract worth $1bn (£555m). And Acambis's lawyers are drawing up a robust defence that claims the US government itself gave the company the detailed scientific knowledge it has used. That science is not patent-protected, Acambis will argue.

Details of Bavarian Nordic's specific allegations have emerged in court papers from the US. These say Acambis's chief scientific officer, Thomas Monath, and a team from the company were shown details of clinical data, dosing and production conditions for the weakened smallpox vaccine - MVA - at a meeting at Acambis's offices on 12 June 2002. The companies signed a "secrecy agreement" before the meeting, it is alleged. Acambis requested a licensing proposal, but backtracked, it is claimed.
The two sides were negotiating a deal whereby Acambis would license intellectual property surrounding MVA. But Acambis signed a deal with the US government's National Institutes of Health (NIH), which had been working on MVA. Bavarian says the NIH was using its secrets, which were not the US government's to sign away.

It tried unsuccessfully to prevent the NIH from releasing its MVA strain to Acambis, the court documents reveal. "The virus was originally provided to Dr Moss [Bernard Moss of the NIH] for research and not for commercialisation into vaccine products," it claims.

The NIH was keen to generate a competitive tender for the contract to supply up to 80 million doses of MVA, which could be worth $1bn. It faced domestic criticism for awarding a contract for a stockpile of anthrax drugs to a single supplier, and it is expected that the MVA contract will be shared between Acambis and Bavarian Nordic.

Acambis refused to comment yesterday on the specifics revealed in the court documents.

news.independent.co.uk/business/news/...

Ikkedike 20 mei 2022 09:59

Het apenpokvirus ! Gisteren hier ingestapt

Ikkedike 21 mei 2022 07:38

18% gestegen , nabeurs 10%

Ikkedike 22 mei 2022 12:59

ben ik de enige instapper hier ?

Ikkedike 21 juli 2022 07:15

sedert gisteren , al 54% winst

Ikkedike 21 juli 2022 09:11

weer aant stijgen gogogo

Ikkedike 23 juli 2022 16:33

WHO verklaart zich snel verspreidende uitbraak van apenpokken tot wereldwijde gezondheidsnoodsituatie!!!!
www.cnbc.com/2022/07/23/who-declares-...

Ikkedike 25 juli 2022 18:22

weer 4% erbij vandaag

Ikkedike 26 juli 2022 17:55

we doen lekker verder 2,5% erbij

Ikkedike 1 augustus 2022 18:49

Lap ! 10%

Pitmans 1 augustus 2022 23:40

Toch vreemd :

Sanofi to acquire Acambis for $546M
Jul 25, 2008 02:30pm

**EDIT** ah ok, deze finance.yahoo.com/quote/BAVA.CO/

Pitmans 13 augustus 2022 09:45

Wat ben je stil nu. Binnen een week 20% eraf vanaf de top. Zou dat het zijn ?

Ikkedike 16 augustus 2022 18:29

ach neen hoor, ik was op verlof. Heb nog al mijn aandeeltjes. Dit is pas het begin !!

Ikkedike 19 augustus 2022 09:03

en we stijgen verder ............................

Pitmans 15 oktober 2022 11:09

$361 op 19 aug, $214 nu. Dat is niet bepaald stijgen.
Maar ja, het marktsentiment zit gewoon wat tegen.

15 Posts

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

AEX 897,42 -5,12 -0,57% 13:10


Germany40^	22.647,70	+0,12%
BEL 20	4.331,54	-0,67%
Europe50^	5.375,13	-0,22%
US30^	42.018,80	+0,15%
Nasd100^	19.508,50	+0,32%
US500^	5.632,42	+0,19%
Japan225^	36.804,00	+1,05%
Gold spot	2.913,10	+0,99%
EUR/USD	1,0905	+0,64%
WTI	66,79	+1,34%